We are a medical device company focused on transforming vascular closure for the benefit of patients, hospitals and physicians. Our products address the over 5.6 million catheter-based coronary, peripheral and electrophysiology procedures in the United States that require vascular access site closure each year. We have purposefully built and optimized our VASCADE family of products to address the key clinical and economic challenges of manual compression, the traditional standard of care for vascular closure in these procedures.

Designed around an easy to use, catheter-based delivery system and the natural clot-inducing properties of collagen, our VASCADE device is the only marketed vascular closure device clinically proven to both increase workflow efficiency and reduce access site complications relative to manual compression for coronary and peripheral procedures. Similarly, our VASCADE MVP device is the only marketed vascular closure device clinically proven and labeled to improve workflow relative to manual compression for electrophysiology procedures. Importantly, these improvements drive meaningful cost savings for our customers, which consist of hospitals, ambulatory surgery centers and other treatment facilities. We believe our substantial body of clinical evidence supports the compelling value proposition of our products and will drive their continued adoption in the $1.4 billion annual addressable U.S. market for vascular access site closure in coronary, peripheral and electrophysiology procedures.

Catheter-based, minimally invasive alternatives to open surgery have transformed cardiovascular medicine. The majority of these procedures gain access to the vascular system through the large femoral artery or vein in the patient’s groin, which creates an access site opening in the vessel that requires closure. In 2019 in the United States, there were approximately 5.2 million catheter-based coronary and peripheral procedures, and 400,000 catheter-based electrophysiology procedures, the latter of which generally require two to five access sites per procedure.